Rpl35 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Rpl35 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@de2023]
Gene Overview
RPL35 (Ribosomal Protein L35) is a gene encoding a ribosomal protein that is a component of the 60S large ribosomal subunit. Located at chromosome 9p22.1, RPL35 encodes a 110-amino acid protein that is essential for ribosome function. Mutations in RPL35 are associated with Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome. [@wang2015]
Gene Information
Normal Function
RPL35 is a ribosomal protein component of the 60S large ribosomal subunit. It plays essential roles in:
Protein synthesis - As part of the 60S subunit, RPL35 participates in the peptidyl transferase activity during protein translation
Ribosome assembly - RPL35 is required for proper 60S subunit biogenesis
Translation termination - The protein contributes to the release of the nascent polypeptide from the ribosome
RPL35 is located in the peptidyl transferase center of the 60S subunit, where it interacts with the tRNA binding sites.
Disease Associations
RPL35 mutations have been associated with:
Diamond-Blackfan anemia (DBA) - RPL35 is one of the ribosomal protein genes implicated in DBA, characterized by impaired erythropoiesis
Ribosomopathies - Inherited disorders of ribosome biogenesis
Cancer - Altered ribosomal protein expression can affect cell proliferation and survival
Molecular Mechanisms
Ribosomal Function
RPL35 contributes to the structure and function of the 60S subunit through:
Interaction with 28S rRNA
Participation in the peptidyl transferase center
Role in translation elongation and termination
Disease Mechanisms in DBA
In DBA, ribosomal protein gene mutations lead to:
Impaired ribosome biogenesis
Ribosomal stress leading to p53 activation
Selective vulnerability of erythroid precursor cells
Clinical Significance
Diamond-Blackfan Anemia
RPL35-related DBA features include:
Macrocytic anemia
Reticulocytopenia
Possible congenital anomalies
Increased cancer risk
Treatment Approaches
Corticosteroids
Red blood cell transfusions
L-leucine therapy
Hematopoietic stem cell transplantation
Research Directions
Understanding the mechanism of ribosomal stress response
Developing new therapeutic approaches for DBA
Studying the role of RPL35 in cancer
Overview
Rpl35 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Rpl35 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
[Gazda HT, Sheen MR, Vlachos A, et al, Ribosomal protein L5 and L11 mutations are associated with cleft palate and progressive phenotypes in Diamond-Blackfan anemia (2008)](https://doi.org/10.1016/j.ajhg.2008.11.006)
[De Keersmaecker K, Sulima SO, Mills GB, Ribosomal mutations and cancer (2023)](https://doi.org/10.1038/s41568-023-00502-8)
[Wang W, Nag S, Zhang X, et al, Ribosomal proteins: functions beyond the ribosome (2015)](https://doi.org/10.1093/jmcb/mjv014)
[Narla A, Ebert BL, Ribosomal mutations and the pathogenesis of Diamond-Blackfan anemia (2008)](https://doi.org/10.1182/blood-2008-02-140012)
[Vlachos A, Blanc L, Lipton JM, Diamond-Blackfan anemia: a model for the translational approach (2014)](https://doi.org/10.4172/2161-1025.1000121)
[Mills GB, Zhang Y, De Keersmaecker K, Ribosomal proteins as tumor suppressors (2016)](https://doi.org/10.18632/oncotarget.11518)
[Choesmel V, Bacqueville D, Rouquette J, et al, Impaired ribosome biogenesis in Diamond-Blackfan anemia (2007)](https://doi.org/10.1182/blood-2006-07-038372)